Clive A. Meanwell

2016

In 2016, Clive A. Meanwell earned a total compensation of $6.7M as Chief Executive Officer at Medicines, a 29% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$853,418
Option Awards$3,450,640
Salary$896,447
Stock Awards$1,500,016
Other$2,935
Total$6,703,456

Meanwell received $3.5M in option awards, accounting for 51% of the total pay in 2016.

Meanwell also received $853.4K in non-equity incentive plan, $896.4K in salary, $1.5M in stock awards and $2.9K in other compensation.

Rankings

In 2016, Clive A. Meanwell's compensation ranked 1,003rd out of 14,075 executives tracked by ExecPay. In other words, Meanwell earned more than 92.9% of executives.

ClassificationRankingPercentile
All
1,003
out of 14,075
93rd
Division
Manufacturing
334
out of 5,489
94th
Major group
Chemicals And Allied Products
87
out of 1,895
95th
Industry group
Drugs
58
out of 1,538
96th
Industry
Pharmaceutical Preparations
49
out of 1,176
96th
Source: SEC filing on April 26, 2017.

Meanwell's colleagues

We found four more compensation records of executives who worked with Clive A. Meanwell at Medicines in 2016.

2016

Stuart Kingsley

Medicines

Chief Operating Officer

2016

Christopher Cox

Medicines

Chief Corporate Development Officer

2016

William O'Connor

Medicines

Chief Financial Officer

2016

Stephen Rodin

Medicines

General Counsel

In-depth

You may also like